Literature DB >> 21196413

Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.

Riyaz Basha1, Cheryl H Baker, Umesh T Sankpal, Sarfraz Ahmad, Stephen Safe, James L Abbruzzese, Maen Abdelrahim.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are primarily used for the treatment of acute or chronic conditions with pain and inflammation. Evidence from a wide range of sources suggested that chronic administration of NSAIDs reduced the risk of cancer incidences. Both the epidemiological and animal studies showed an inverse association between the incidence of various cancers and the use of aspirin or other NSAIDs. The chemopreventive and therapeutic interventions of NSAIDs in cancer are obvious; however, the instigation of drug and treatment period depends on the study objective. Typically, prevention involves initiating the medication before the appearance of clinical symptoms and lasts long-term; while treatment could be short-term and contingent to the response of patient to the medication. Recent studies from our laboratories provided substantial evidence on the anti-cancer activity of tolfenamic acid, a NSAID for the potential applications in pancreatic, esophageal and lung cancers. In this review, we provide a summary on the potential benefits of NSAIDs in a variety of human cancers with more emphasis on tolfenamic acid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196413     DOI: 10.2741/s188

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  10 in total

1.  Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Authors:  Myrna Hurtado; Laszlo Prokai; Umesh T Sankpal; Blair Levesque; Rajasekhar Maram; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Process Biochem       Date:  2019-10-30       Impact factor: 3.757

2.  Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.

Authors:  Myrna Hurtado; Umesh T Sankpal; Aboubacar Kaba; Shahela Mahammad; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Cell Physiol Biochem       Date:  2018-11-30

3.  Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.

Authors:  Don Eslin; Chris Lee; Umesh T Sankpal; Pius Maliakal; Robert M Sutphin; Liz Abraham; Riyaz Basha
Journal:  Tumour Biol       Date:  2013-05-18

4.  Anti-leukemic response of a NSAID, tolfenamic acid.

Authors:  Robert M Sutphin; Sarah F Connelly; Chris M Lee; Umesh T Sankpal; Don Eslin; Moeez Khan; Hima Pius; Riyaz Basha
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

5.  Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver.

Authors:  Mohammed I Shukoor; Samata Tiwari; Umesh T Sankpal; Pius Maliakal; Sarah F Connelly; Shaila Siddiqi; Shadab A Siddiqi; Riyaz Basha
Journal:  Integr Biol (Camb)       Date:  2012-07-26       Impact factor: 2.192

Review 6.  Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs.

Authors:  Stephen H Safe; Paul L Prather; Lisa K Brents; Gayathri Chadalapaka; Indira Jutooru
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

7.  P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach.

Authors:  France Massicot; Guillaume Hache; Ludivine David; Dominique Chen; Charlotte Leuxe; Laure Garnier-Legrand; Patrice Rat; Olivier Laprévote; François Coudoré
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells.

Authors:  Haley L Peters; Amit Tuli; Xiaojian Wang; Cuiling Liu; Zenggang Pan; Michel M Ouellette; Michael A Hollingsworth; Richard G Macdonald; Joyce C Solheim
Journal:  Int J Oncol       Date:  2012-07-13       Impact factor: 5.650

9.  Anti-inflammatory effects of 81 chinese herb extracts and their correlation with the characteristics of traditional chinese medicine.

Authors:  Chang-Liang Chen; Dan-Dan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-20       Impact factor: 2.629

10.  Effects of celecoxib on cell apoptosis and Fas, FasL and Bcl-2 expression in a BGC-823 human gastric cancer cell line.

Authors:  Qian Li; Jie Peng; Ting Liu; Guiying Zhang
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.